Public Market Listing
Live quotes, historical charts, and market capitalization for Shanghai Pharmaceuticals Holding are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(2 total)
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $30.1B | $212M | $5.2B | — | report ↗ |
Shanghai Pharmaceuticals Holding reported revenue of $30,052.64M, up 2.7% YoY, R&D spend of $211.76M, down 6.1% YoY, and cash and equivalents of $5,160.04M for Q3 2025.
Figures only: this period's report disclosed no narrative text
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-H1 | $19.5B | $132M | $5.5B | — | report ↗ |
| 2025-Q1 | $9.7B | $68M | $5.0B | — | report ↗ |
| 2024-Q3 | $29.3B | $226M | $4.8B | — | report ↗ |
| 2024-H1 | $19.4B | $154M | — | — | report ↗ |
| 2024-Q1 | $9.8B | $70M | $4.2B | — | report ↗ |
| 2023-Q3 | $27.3B | $203M | $4.0B | — | report ↗ |
| 2023-H1 | $19.2B | $148M | — | — | report ↗ |
| 2023-Q1 | $9.7B | $79M | $3.9B | — | report ↗ |
| 2022-Q3 | $25.5B | $203M | $3.6B | — | report ↗ |
| 2022-H1 | $17.3B | $125M | $4.0B | — | report ↗ |
| 2022-Q1 | $9.0B | $71M | $5.8B | — | report ↗ |
| 2021-Q3 | $24.9B | $211M | $3.6B | — | report ↗ |
| 2021-H1 | $16.3B | $136M | $3.5B | — | report ↗ |
| 2021-Q1 | $8.0B | $64M | $3.4B | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $41.9B | $345M | $4.8B | — | report ↗ |